AHR and neoplasm: Recently, Sadik and co-workers proposed that IL4I1 expression may also underlie the resistance of patients against IDO1 inhibition, with activation of the AhR presented as their common mechanism of immune response blockade and promotion of tumor cell malignancy [18].